Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.CBIO · Entity 5255 | See Remarks | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 18,710 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 620 · Balance 18,710 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 20:02 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | SaleOrdinary Shares | 620 | $17.90 | $11,098.00 |
DisclosureSEC source: 0001628280-26-062703 · wk-form4_1789761740.xml · nonDerivative · entry 1 Bispham Barbara Harlin · CIK 0002075230 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,710 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 22, 2026 Filed Jun 23, 2026 20:03 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | SaleOrdinary Shares | 1,218 | $17.99 | $21,911.82 |
DisclosureSEC source: 0001628280-26-044887 · wk-form4_1782245005.xml · nonDerivative · entry 1 Bispham Barbara Harlin · CIK 0002075230 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,330 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:35 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantStock Option (Right to Buy) · Derivative | 72,185 | $0.00 Strike: $13.21 | $0.00 |
DisclosureSEC source: 0001628280-25-057669 · wk-form4_1766007333.xml · derivative · entry 3 Bispham Barbara Harlin · CIK 0002075230 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,185 Underlying: Ordinary Shares · 72,185 shares Expires 2035-12-15 F2 · derivative.exercise_date: This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:35 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantOrdinary Shares | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-057669 · wk-form4_1766007333.xml · nonDerivative · entry 2 Bispham Barbara Harlin · CIK 0002075230 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,422 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:35 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantOrdinary Shares | 12,422 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-057669 · wk-form4_1766007333.xml · nonDerivative · entry 1 Bispham Barbara Harlin · CIK 0002075230 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,422 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.